Company news
Genprex, Inc. news in 2024
Genprex, Inc.'s news releases, calls and decks from 2024, newest first.
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
December 15, 2024
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
November 19, 2024
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
October 23, 2024
Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
October 14, 2024
Genprex Announces Formation of Mesothelioma Clinical Advisory Board
September 18, 2024
Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
September 3, 2024
Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer
August 13, 2024
Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers
August 12, 2024
Genprex to Present at the 2024 BIO International Convention
May 29, 2024
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
May 13, 2024
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors
May 12, 2024
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
May 7, 2024
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
April 2, 2024
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
March 18, 2024
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
March 11, 2024
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
February 6, 2024
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
February 4, 2024
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
January 30, 2024
Genprex Provides Business Update and Outlook for 2024
January 4, 2024
Decks in 2024
- Investor Presentation (June 2024)
Investor deck · 57 slides · June 2024
- Investor Presentation (January 2024)
Investor deck · 52 slides · Jan 5, 2024